{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-050887","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.800745+00:00","generated_at":"2026-06-03T02:45:29.657994+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alkermes Q1 2024 revenue $350.4M, GAAP net income $38.9M, LYBALVI sales up 50% YoY","bullets":["Total revenues of $350.4M vs $287.6M in Q1 2023; GAAP net income from continuing ops $38.9M ($0.23 EPS) vs loss of $12.1M.","LYBALVI net sales $57.0M (+50% YoY); VIVITROL $97.7M; ARISTADA $78.9M; royalty revenue $62.7M from J&J sublicense.","Non-GAAP net income from continuing ops $76.2M vs $30.1M; cash & investments $807.8M, debt $290.1M.","R&D expense $67.6M (+6%) driven by ALKS 2680; SG&A $179.7M (+7%) on LYBALVI DTC campaign.","Company reiterates 2024 financial expectations; positive phase 1b data for ALKS 2680 in narcolepsy type 2."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-050887","json":"https://secwatch.observer/filing/0000950170-24-050887.json","markdown":"https://secwatch.observer/filing/0000950170-24-050887.md","text":"https://secwatch.observer/filing/0000950170-24-050887.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024050887/0000950170-24-050887-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024050887/alks-20240501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:45:29.657994+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"51bc1ab97661b7b0b1b65b9644b11238aeaeee6f","claim":"Alkermes plc. updated its first quarter of 2024 guidance (reaffirmed).","evidence_excerpt":"On May 1, 2024, Alkermes plc (the “Company”) announced financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017024050887/0000950170-24-050887-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}